3 Feb 2020 10:30
03 February 2020
RNS REACH
Open Orphan plc
("Open Orphan", the "Company" or the "Group")
New Corporate Presentation
Open Orphan plc (ORPH), the rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce the latest copy of its investor presentation is now available to view on https://www.openorphan.com/investors/reasons-invest.
Open Orphan was also covered this weekend in the Sunday Times due to our unique reputation as being the world leader in this space having provided services for over 30 years to the vaccine production companies around the world.
https://www.thetimes.co.uk/article/irish-firm-open-orphan-lined-up-for-role-in-coronavirus-fight-kgrnkp3f5
For further information please contact
Open Orphan plc Cathal Friel, Executive Chairman Trevor Phillips, Chief Executive Officer |
+353 (0)1 644 0007 +44 (0)20 7347 5350 |
|
|
Arden Partners plc (Nominated Adviser and Joint Broker) John Llewellyn-Lloyd / Benjamin Cryer | +44 (0)20 7614 5900 |
|
|
Davy (Euronext Growth Adviser and Joint Broker) Anthony Farrell | +353 (0)1 679 6363 |
|
|
Camarco (Financial PR) |
|
Tom Huddart / Daniel Sherwen | +44 (0)20 3757 4980 |
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
ORPH.L (ORPH)